MedPath

Cognitive-Behavioral Therapy for Children With Nightmares

Not Applicable
Recruiting
Conditions
Children, Only
Nightmare
Suicidal Ideation
Interventions
Behavioral: Cognitive Behavioral Therapy for Nightmares in Children
Registration Number
NCT06033781
Lead Sponsor
University of Oklahoma
Brief Summary

The goal of this clinical trial is to assess the efficacy of CBT-NC intervention to determine its impact on mental health and suicidality in children ages 6-17. The main aims are:

Aim 1: Examine CBT-NC efficacy for improving nightmare distress and frequency in youth with chronic nightmares by comparing the treatment and waitlist group.

Aim 2: Examine whether improvements in nightmares relate to fewer mental health problems for youth by determining by comparing the treatment and waitlist group.

Detailed Description

Chronic nightmares in youth put them at risk for mental health problems including suicidal ideation and attempts. Left untreated, chronic childhood nightmares can persist, resulting in myriad mental health problems. An international consortium of nightmare experts urged the medical community to prevent mental health problems in youth through early detection and treatment of chronic nightmares. There are several well-established, brief, and cost-effective nightmare treatments for adults but research with youth is lagging. To date, several small case series have investigated nightmare treatments for youth and there is a need for clinical trials. The proposed study will evaluate the efficacy of Cognitive Behavioral Therapy for Nightmares in Children (CBT-NC), a brief five-session manualized therapy designed to treat children ages 6-17. This randomized controlled trial with treatment and waitlist arms will assess the efficacy of the intervention and determine if the intervention has any impact on mental health problems and suicidality at follow-up.

This study will be the first randomized controlled trial to assess the efficacy of Cognitive behavioral therapy for nightmares in children (CBT-NC), compared to a waitlist group. Our goal is to determine whether CBT-NC can be an effective treatment strategy for reducing nightmares in youth, which are linked to suicidality.

First, this study will address the need for efficacious and cost-effective treatment for improving nightmare distress and frequency in youth with chronic nightmares. Second, this study will determine if improvements in nightmares reduce risk for youth mental health problems including suicidal ideation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Child must be between ages of 6-17 years 11 months.
  • Child must report recurrent nightmares that meet Diagnostic and Statistical Manual of Mental Disorders criteria for nightmare disorder.
  • Child must speak and understand English at no less than a 6-year-old level.
  • Children on prescribed psychotropic medications must be stable for 30 days prior to enrolling.
  • Child must have a parent or legal guardian attend study visits with them.
  • Participants must have access to WIFI/phone data in order to participate in this study and must have an electronic device with a camera enabled.
Exclusion Criteria
  • Children with a diagnosis of sleep apnea which is not adequately treated.
  • Children whose receptive/expressive language skills are below a 6-year-old level.
  • If it is determined that a child is actively suicidal and at imminent risk for self-harm, the family will be notified and referred for immediate care. They will not be eligible for the study until they are deemed stable.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment Right-AwayCognitive Behavioral Therapy for Nightmares in ChildrenChild will start the CBT-NC treatment right away.
Primary Outcome Measures
NameTimeMethod
Change on the Columbia Suicide Severity Rating Scale (C-SSRS)Participants will be assessed at baseline (Week 0), at post-assessments, up to 20 weeks, and weekly following their post-assessment for 4 weeks.

The C-SSRS is a yes/no questionnaire to assess for suicidal ideations and behaviors. For this study, we will be looking at the 5 suicidal ideation questions.

Change on the Strengths and Difficulties Questionnaire (SDQ) - Caregiver VersionParticipants' caregivers will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

The SDQ is a 25-item brief behavioral screening questionnaire for detecting mental health problems in general populations people aged 2-17. It assesses three scales for internalizing problems (10 items), externalizing problems (10 items), and prosocial behavior (5 items). The internalizing and externalizing scales have scores ranging from 0 to 20 with higher scores indicating more difficulties. The prosocial behavior scale ranges from 0 to 10 with higher scores indicating more prosocial behaviors.

Changes in reports on Sleep JournalParticipants complete this daily from consent to baseline assessment (Week 0), during treatment, and before post-assessments, up to 20 weeks. They also complete a weekly version for 4 weeks following post-assessments (Weeks 10-14).

The sleep journal is a 3 question self report regarding nightmares.

Change in Nightmare Disorder Diagnoses from Structure Clinical Interview for Sleep Disorders in Children (SCISD-Kid)Participants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

The SCISD-Kid is a structured clinical interview that assesses for sleep disorders. The main module interest is the nightmare disorder module.

Change on the Patient Health-Questionnaire-9 (PHQ-9)Participants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

The PHQ-9 is a 9-question Likert scale questionnaire to assess for depression. The items are scored on a scale of 0-27. Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe, and severe depression, respectively.

Secondary Outcome Measures
NameTimeMethod
Change on the Child Adolescent Trauma Screen (CATS) - Caregiver VersionParticipants' caregivers will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

The CATS screens for child trauma history and PTSD symptoms in youth ages 7-17; 15 YES/NO questions; 1 open-ended question

Change on Sleep Locus of Control (SLOC)Participants and caregivers will be assessed at Baseline (Week 0), post-assessments, and weekly during therapy, up to 20 weeks.

The SLOC is a 5 item self report measure perceived contingencies between sleep behavior and events. This scale is collected as a child self report, and a caregiver report regarding child. The items are answered with a 1-5 Likert scale with total scores ranging from 5 to 25. Higher scores indicate higher locus of control.

Change on the Child Adolescent Trauma Screen (CATS) - Child VersionParticipants will be assessed at baseline (Week 0) and at post-assessments, up to 20 weeks.

The CATS screens for child trauma history and PTSD symptoms in youth ages 7-17; 15 YES/NO questions; 1 open-ended question

Change on the Patient Health-Questionnaire-2 (PHQ-2)Participants will be assessed at baseline (Week 0), at post-assessments, up to 20 weeks, and weekly following their post-assessment for 4 weeks.

The PHQ-9 is a 2-question Likert scale questionnaire to screen for depression. Scores range from 0-6. A score of 3 or greater indicates major depressive disorder may exist.

Change on Nightmare Locus of Control (NLOC)Participants and caregivers will be assessed at Baseline (Week 0), post-assessments, and weekly during therapy, up to 20 weeks.

The NLOC is a 5 item self report measure regarding nightmare behavior and events. This scale is collected as a child self report, and a caregiver report regarding child. The items are answered with a 1-5 Likert scale with total scores ranging from 5 to 25. Higher scores indicate higher locus of control.

Trial Locations

Locations (2)

University of Tulsa

🇺🇸

Tulsa, Oklahoma, United States

University of Oklahoma School of Community Medicine

🇺🇸

Tulsa, Oklahoma, United States

© Copyright 2025. All Rights Reserved by MedPath